Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.1.1.6 extracted from

  • Zoccolella, S.; Iliceto, G.; deMari, M.; Livrea, P.; Lamberti, P.
    Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review (2007), Clin. Chem. Lab. Med., 45, 1607-1613.
    View publication on PubMed

Application

Application Comment Organism
medicine L-dopa treatment is an acquired cause of hyperhomocysteinemia. The mechanism underlying L-dopa-related hyperhomocysteinemia is the O-methylation of the drug catalyzed by the enzyme catechol-O-methyltransferase. L-Dopa is the gold standard in the symptomatic management of Parkinson’s disease, but its long-term treatment is complicated by the elevation in plasma homocysteine concentrations, due to the O-methylation by COMT Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Synonyms

Synonyms Comment Organism
COMT
-
Homo sapiens